concanamycin a

Concanamycin A (Folimycin), a polycyclic lactone antibiotic, is a selective inhibitor of vacuolar H+-ATPase (V-ATPase) and lysosomal acidification, and can be used to study inflammation.Concanamycin A enhances the immune clearance of infected progenitor cells by cytotoxic T lymphocytes, and inhibits Nef et al. from different branches of HIV and simian immunodeficiency virus. Concanamycin A enhances immune clearance of cytotoxic T lymphocytes from infected progenitor cells, inhibits the Nef allele from different branches of HIV and simian immunodeficiency virus, and can be used to study HIV infection.

Concanamycin B is a macrolide antibiotic that selectively inhibits vacuolar type H+-ATPases (IC50 = 5 nM), thereby blocking vacuolar organelle acidification and early to late endosomal transport. It interferes with bone resorption, maturation of CD8 T lymphocytes, and prevents processing of major histocompatibility complex (MHC) class II precursors in human B cells, inhibiting MHC class II molecule expression on the cell surface.

Concanamycin F exhibits antifungal, antiviral, immunosuppressive, and cytotoxic activities and is a specific inhibitor of V-type ATPase with a Ki of 0.02 nM.

Concanamycin C, a natural macrolide antibiotic, was initially isolated from Streptomyces and identified as an inhibitor of T-cell proliferation in response to concanavalin A (1,2). It exhibits cytotoxicity to fungi, including yeasts, by inhibiting vacuolar-type ATPases (3,4).

Concanamycin G exhibits antifungal, antiviral, immunosuppressive, and cytotoxic activities, and is a specific inhibitor of V-type ATPase with a Ki of 0.02 nM.

Concanamycin E is an inhibitor of lysosomal acidification with an IC50 value of 0.085 nM.

Concanamycin D is an inhibitor of lysosomal acidification with an IC50 value of 0.085 nM.